A Phase I Study to Investigate the Safety Profile and the Efficacy of EDO-S101, a First-in-Class Alkylating HDACi Fusion Molecule in Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Tinostamustine (Primary)
- Indications CNS cancer; Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions
- 01 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
- 13 Jun 2018 Planned initiation date changed from 1 Jun 2018 to 1 Jul 2018.
- 12 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Jun 2018.